# NKG2D
**NKG2D** (natural killer group 2, member D) is an activating, lectin-like type II transmembrane receptor encoded by the *Klrk1* gene that is expressed on natural killer (NK) cells, CD8+ T cells, γδ T cells, NKT cells, and some myeloid cells, and that recognizes cell-surface stress ligands related to [MHC class I](https://www.edgepedia.org/mhc-class-i) molecules[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/) • [2](https://www.nature.com/articles/nri1199). It is one of the best-characterized receptors associated with immune responses to cellular distress, defined as transformation, infection, or cell stress[2](https://www.nature.com/articles/nri1199).
| Key fact | Detail |
|---|---|
| Receptor type | Lectin-like type II transmembrane stimulatory immunoreceptor with a charged transmembrane residue that enables interaction with signaling adaptors[2](https://www.nature.com/articles/nri1199) |
| Gene | Killer cell lectin-like receptor subfamily K member 1 (*Klrk1*)[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/) |
| Expression | All NK cells in mice and humans; constitutive on human CD8+ T cells but expressed on mouse CD8+ T cells only after activation; also NKT cells, γδ T cells, activated murine macrophages, and a small subset of CD4+ T cells[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/) |
| Human ligands | MICA, MICB, and ULBP1–6 (RAET1 proteins), distantly related to MHC class I[2](https://www.nature.com/articles/nri1199) |
| Mouse ligands | Rae1ε family, H60a–c, and Mult1[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/) • [2](https://www.nature.com/articles/nri1199) |
| Signaling | Associates with DAP10 in most cells; in CD8+ T cells signals exclusively through DAP10, while mouse NK cells can also use a DAP12-paired splice isoform[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/) • [2](https://www.nature.com/articles/nri1199) |
| Functional mode | Sufficient on its own to trigger NK-cell killing; in CD8+ T cells it costimulates, requiring concurrent T-cell receptor (TCR) activation[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/) |
## Structure and signaling
NKG2D contains a charged transmembrane residue that lets it interact with signaling adaptor molecules[2](https://www.nature.com/articles/nri1199). In most NKG2D-positive cells it associates with DNAX-activating protein of 10 kDa (DAP10), an adaptor whose YXXM tyrosine-based motif recruits the p85 subunit of phosphatidylinositol 3-kinase (PI3K) and the adaptor Grb2[2](https://www.nature.com/articles/nri1199) • [3](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2015.00097/pdf). The NKG2D–DAP10 complex is a hexameric structure with two NKG2D molecules linked to a total of four DAP10 adaptors, held together by salt bridges between complementary charged transmembrane residues[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/) • [4](https://pmc.ncbi.nlm.nih.gov/articles/PMC10452210/).
In mouse NK cells and macrophages, an alternatively spliced NKG2D isoform can associate with DAP12, an adaptor that recruits and activates the SYK and [ZAP70](https://www.edgepedia.org/zap70) tyrosine kinases; DAP12 signaling is required for normal cytokine production and optimal cytolysis by mouse NK cells[2](https://www.nature.com/articles/nri1199). In CD8+ T cells, NKG2D cannot function without DAP10; however, mouse NK cells lacking DAP10 remain strongly cytolytic, indicating that DAP10 does not account for all NK-cell signaling[2](https://www.nature.com/articles/nri1199).
Receptor endocytosis is part of the regulatory cycle. Ligand engagement activates the ubiquitin ligase c-Cbl and promotes DAP10 ubiquitination, which triggers NKG2D internalization and lysosomal degradation and ultimately hyporesponsiveness toward ligand-bearing target cells; internalization can, however, also physically approximate DAP10 to ERK1/2 and contribute to signaling[5](https://pubmed.ncbi.nlm.nih.gov/28767057/) • [6](https://pmc.ncbi.nlm.nih.gov/articles/PMC7754731/).
## Ligands and recognition of stressed cells
NKG2D is a promiscuous receptor that binds several families of ligands distantly related to MHC class I molecules[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/) • [2](https://www.nature.com/articles/nri1199). In humans these are MICA and [MICB](https://www.edgepedia.org/micb), encoded in the MHC, and the UL16-binding proteins (ULBPs, also called RAET1 proteins); in mice they are the Rae1 family, H60, and Mult1[2](https://www.nature.com/articles/nri1199). Although the ligands usually appear at low levels on healthy cells, their expression rises on malignant, infected, and sometimes stressed cells, for example during viral infection or DNA damage[2](https://www.nature.com/articles/nri1199) • [1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/). Crystal structures show that NKG2D binds diagonally over the α1 and α2 helices of its ligands, much as T-cell receptors bind over MHC molecules, and some key ligand residues that contact NKG2D are conserved despite poor sequence homology among the ligands[2](https://www.nature.com/articles/nri1199).
Unlike the ligands of the costimulatory receptor CD28 (CD80/CD86), which are restricted to antigen-presenting cells, NKG2D ligands can be expressed in any cell type upon stress[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/). This widespread ligand expression is one reason the receptor has attracted interest as a target in immunotherapy[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/).
## Roles in NK cells and CD8+ T cells
The functional outcome of NKG2D engagement differs by cell type. In NK cells, NKG2D signaling alone is sufficient to unleash the killing response; in CD8+ T cells, it requires concurrent activation of the [T-cell receptor](https://www.edgepedia.org/t-cell-receptor), and its role is to authenticate recognition of a stressed target and enhance TCR signaling[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/). On T cells exposed to inflammatory cytokines such as IL-15, NKG2D signaling may in some cases suffice for triggering[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC3868205/). IL-15 signaling regulates NKG2D expression, increases DAP10 expression, and phosphorylates the adaptor to prime NKG2D signaling[3](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2015.00097/pdf).
NKG2D is often compared with CD28, the archetype costimulatory receptor of T-cell priming. In humans both receptors are found on CD8+ T cells, but NKG2D is expressed by all CD8+ T cells whereas CD28 is expressed by about 50% of mature human CD8+ T cells (and about 95% of human CD4+ T cells)[1](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/). Their signaling differs as well: the NKG2D–DAP10 complex does not activate LAT, an adaptor central to TCR signaling, in NK cells, whereas CD28 has been shown to induce LAT phosphorylation[8](https://www.nature.com/articles/cmi2017161.pdf). NKG2D has been associated with IL-15 receptor signaling and with memory CD8 T-cell formation, although one study found that memory generation and expansion were independent of NKG2D while effector responses of reactivated memory T cells were substantially enhanced by it[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC5852076/) • [8](https://www.nature.com/articles/cmi2017161.pdf).
## Cancer immunity and immune evasion
When tumor-cell lines display NKG2D ligands, NK cells, and occasionally T cells, efficiently reject them in vivo, and a durable T-cell response is generated that protects against later challenge with the original ligand-negative tumor[2](https://www.nature.com/articles/nri1199). NKG2D-deficient mice are more susceptible to spontaneous tumor development in the TRAMP prostate cancer and Eµ-myc lymphoma transgenic models, supporting a role in tumor immune surveillance[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC10452210/).
Tumors evade this axis in several ways. Metalloproteases, most prominently ADAM10, ADAM17, and MMP14, cleave MICA, MICB, or ULBP proteins from the tumor-cell surface, and the disulfide-isomerase ERp5 facilitates this shedding; shedding of even a single ligand can render immune cells unresponsive to the entire ligand family[10](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.02040/full). GPI-anchored ligands such as ULBP1 and ULBP3 are also released in exosomes[10](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.02040/full). Soluble MICA down-modulates surface NKG2D on effector NK and T cells, destabilizes the CD3ζ signaling component on CD8 T cells, and skews macrophages toward a tumor-promoting phenotype[11](https://pmc.ncbi.nlm.nih.gov/articles/PMC6145810/). Chronic ligand engagement likewise down-modulates NKG2D on tumor-infiltrating lymphocytes and reduces responsiveness to engagement[9](https://pmc.ncbi.nlm.nih.gov/articles/PMC5852076/). The role of ligand expression in human cancer prognosis has been controversial: studies of colorectal, cervical, and nasopharyngeal carcinoma correlated high surface ligand expression with improved disease-free survival, while other work supports a negative regulatory role for membrane-bound ligands through chronic stimulation[12](https://pmc.ncbi.nlm.nih.gov/articles/PMC6099450/) • [11](https://pmc.ncbi.nlm.nih.gov/articles/PMC6145810/).
Pathogens also manipulate the axis. Certain viral pathogens encode evasion proteins that retain NKG2D ligands intracellularly, and viral mutants lacking these proteins have reduced pathogenicity; human cytomegalovirus UL16 glycoprotein retains MICB and ULBP ligands inside infected cells[2](https://www.nature.com/articles/nri1199).
## Autoimmunity and antifungal immunity
Maintained expression of NKG2D ligands is associated with autoimmune and chronic inflammatory states including rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, demyelinating conditions, and celiac disease[4](https://pmc.ncbi.nlm.nih.gov/articles/PMC10452210/). In rheumatoid arthritis, membrane-bound ligands from synovial fibroblasts drive local effector-cell cytotoxicity while ADAM10-mediated cleavage releases soluble forms that mediate peripheral immunosuppression[13](https://pmc.ncbi.nlm.nih.gov/articles/PMC13154127/). Knockout and antibody-blockade studies indicate that NKG2D plays selective rather than universal roles in inflammatory disease: disease severity in experimental autoimmune encephalitis was reduced in NKG2D-deficient mice at a limiting antigen dose but unchanged at an optimal dose, and no effect was detected in two models of type 1 diabetes or a model of intestinal inflammation[7](https://pmc.ncbi.nlm.nih.gov/articles/PMC3868205/).
A 2024 study gave NKG2D a role in detecting non-self: this receptor binds fungi directly, spanning most major families, among them Candida, Cryptococcus, and [Aspergillus](https://www.edgepedia.org/aspergillus) species, and animals without NKG2D show heightened vulnerability to fungal disease in both invasive and mucosal infection models, establishing NKG2D as an anti-fungal pattern recognition receptor.[14](https://www.nature.com/articles/s41467-024-52913-2) The fungal ligand has not been identified; a screen of 672 lipid-linked carbohydrates found no significant NKG2D binding, arguing against a common cell-wall glycan[14](https://www.nature.com/articles/s41467-024-52913-2).
## Immunotherapy applications
The selective expression of stress-induced ligands on tumors has made the NKG2D–NKG2DL pathway a target for cancer immunotherapy[15](https://www.ajcr.us/files/ajcr0099953.pdf). Approaches include NKG2D-based chimeric antigen receptors, which couple the NKG2D ectodomain to activating signaling modules such as CD3ζ or DAP10/DAP12-based designs; the first-in-human NKG2D-CAR program CYAD-01/NKR-2 (NCT03018405) informed safety strategies such as transient mRNA CAR delivery and suicide switches[16](https://www.nature.com/articles/s41392-026-02873-4). NKG2D is also among the targets pursued in CAR-NK cell trials for hematologic malignancies[17](https://pmc.ncbi.nlm.nih.gov/articles/PMC13141645/), and an NKG2D ligand DNA vaccine combined with temozolomide and radiotherapy is in a phase I trial for newly diagnosed glioblastoma (NCT04290858)[18](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1656570/pdf). Therapeutic strategies against ligand shedding include inhibitors of MMPs and of ADAM10 and ADAM17, which enhance ligand surface expression and promote immune recognition[19](https://pubmed.ncbi.nlm.nih.gov/25050215/).
## References
1. [Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy (Cellular & Molecular Immunology, 2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6068164/)
2. [Raulet, D. H. Roles of the NKG2D immunoreceptor and its ligands. Nature Reviews Immunology 3, 781–790 (2003)](https://www.nature.com/articles/nri1199)
3. [NKG2D ligands in tumor immunity: two sides of a coin (Frontiers in Immunology, 2015)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2015.00097/pdf)
4. [The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10452210/)
5. [Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis (Trends in Immunology, 2016)](https://pubmed.ncbi.nlm.nih.gov/28767057/)
6. [NKG2D and MICA/B shedding: a 'tag game' between NK cells and malignant cells (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7754731/)
7. [A selective role of NKG2D in inflammatory and autoimmune diseases (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3868205/)
8. [Functions of NKG2D in CD8+ T cells (PDF, Cellular & Molecular Immunology)](https://www.nature.com/articles/cmi2017161.pdf)
9. [NKG2D: A Master Regulator of Immune Cell Responsiveness (Frontiers in Immunology, 2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5852076/)
10. [NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy (Frontiers in Immunology, 2018)](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.02040/full)
11. [NKG2D and its ligands in cancer (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6145810/)
12. [The Paradoxical Role of NKG2D in Cancer Immunity (Frontiers in Immunology, 2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6099450/)
13. [Research progress of the ULBP-NKG2D axis in autoimmune diseases (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13154127/)
14. [Charpak-Amikam, Y. et al. The activating receptor NKG2D is an anti-fungal pattern recognition receptor. Nature Communications 15, 8664 (2024)](https://www.nature.com/articles/s41467-024-52913-2)
15. [NKG2D-NKG2DL pathway as an immunotherapy target (American Journal of Cancer Research, 2019)](https://www.ajcr.us/files/ajcr0099953.pdf)
16. [CAR T cell therapy beyond cancer (Signal Transduction and Targeted Therapy, 2026)](https://www.nature.com/articles/s41392-026-02873-4)
17. [CAR-NK cell therapy for hematologic malignancies (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13141645/)
18. [The advantages of NK cell vaccines in solid carcinoma clinical trials (Frontiers in Medicine, 2025)](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1656570/pdf)
19. [Secretory pathways generating immunosuppressive NKG2D ligands (2014)](https://pubmed.ncbi.nlm.nih.gov/25050215/)
---
*Topic: Encyclopedia › Life and health › Biological foundations › Cell biology › Cell death › Death receptor and extrinsic death signaling › NKG2D ligand systems (ULBP and related)*
*Initially written Sep 17, 2026 · Reviewed: Oct 21, 2026 · Edited: Oct 15, 2026; Oct 21, 2026 · Last review: Oct 21, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license